ALISO VIEJO, Calif., March 8 Clarient, Inc. (Nasdaq: CLRT), a premier technology and services resource for pathologists, oncologists and the pharmaceutical industry, today announced that CEO Ron Andrews is scheduled to make an investor presentation at the Roth 22nd Annual OC Growth Stock Conference on Wednesday, March 17, at 9:30 am Pacific Time. The conference is being held March 15-17, at the Ritz Carlton, Laguna Niguel in Dana Point, California.
Advertisement
A live webcast of the presentation will be available via a link provided at http://www.clarientinc.com/investor. An archived replay of the presentation will also be available for a period of 90 days from the date of the presentation at http://www.clarientinc.com/investor.
Advertisement
About Clarient
Clarient combines innovative diagnostic technologies with world-class pathology expertise to assess and characterize cancer. Clarient's mission is to become the leader in cancer diagnostics by collaborating with the healthcare community to translate cancer research and development into better patient care. Clarient's principal customers include pathologists, oncologists, hospitals and biopharmaceutical companies. The rise of individualized medicine has created the need for a centralized resource which provides leading oncology diagnostic technologies, such as flow cytometry and molecular testing. Clarient is that resource, having created a state-of-the-art commercial cancer laboratory, which provides advanced oncology testing and diagnostic services. Resulting diagnostic reports and analyses are made available to customers through Clarient's Internet-based portal, PATHSiTE(TM). Clarient also plans to develop and market new, proprietary "companion" diagnostic markers for therapeutics in breast, prostate, lung and colon cancers, and leukemia and lymphoma. www.clarientinc.com
CONTACT: -------- Matt Clawson Allen & Caron Inc 949.474.4300 [email protected]
SOURCE Clarient, Inc.
